Used in targeted cancer therapies, particularly in prostate and glioblastoma cancers, where TMEFF2 is overexpressed. This reference antibody serves as a critical tool in the development and validation of diagnostic assays and therapeutic antibodies. It enables precise detection and quantification of TMEFF2 in biological samples, supporting research into tumor progression and immune response modulation. In drug development, it acts as a benchmark for affinity and specificity during the optimization of therapeutic antibody candidates. Its high selectivity makes it valuable in immunohistochemistry, flow cytometry, and ELISA applications within preclinical studies.